Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study

Background. The prognosis of pancreatic adenocarcinoma (PAAD) is extremely poor and has not been improved. Thus, an effective method to assess the prognosis of patients must be established to improve their survival rate. Method. This study investigated immune-related genes that could be used as potential therapeutic targets for PAAD. Level 3 gene expression data from the PAAD cohort and the relevant clinical information were obtained from The Cancer Genome Atlas (TCGA) database. For validation, other PAAD datasets (DSE62452) were downloaded from the Gene Expression Omnibus (GEO) database. The PAAD datasets from TCGA and GEO were used to screen immune-related genes through the Molecular Signatures Database using gene set enrichment analysis. Then, the overlapping immune-related genes of the two datasets were identified. Coexpression networks of the immune-related genes were constructed. Results. A signature of three immune-related genes (CKLF, ERAP2, and EREG) was identified in patients with PAAD. The signature could be used to divide the patients with PAAD into high- and low-risk groups based on their median risk score. Multivariate Cox regression analysis was performed to determine the independent prognostic factors of PAAD. Time-dependent receiver operating characteristic (ROC) curve analysis was conducted to assess the prediction accuracy of the prognostic signature. Last, a nomogram was established to assess the individualized prognosis prediction model based on the clinical characteristics and risk score of the TCGA PAAD dataset. The accuracy of the prognostic signature was further evaluated through functional evaluation and principal component analysis. Conclusions. The results indicated that the signature of three immune-related genes had excellent predictive value for PAAD. These findings might help improve personalized treatment and medical decisions.

Download Full-text

The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma

Scientific Reports ◽

10.1038/s41598-021-89747-7 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Lunxu Li ◽

Shilin Xia ◽

Xueying Shi ◽

Xu Chen ◽

Dong Shang

Keyword(s):

Hepatocellular Carcinoma ◽

Network Analysis ◽

Risk Score ◽

Cox Regression ◽

Low Risk ◽

Gene Set Enrichment Analysis ◽

The Cancer Genome Atlas ◽

Prediction Ability ◽

Cox Regression Analysis ◽

Immune Related Genes

AbstractHepatocellular carcinoma (HCC) is one of the main causes of cancer deaths globally. Immunotherapy is becoming increasingly important in the cure of advanced HCC. Thus it is essential to identify biomarkers for treatment response and prognosis prediction. We searched publicly available databases and retrieved 465 samples of genes from The Cancer Genome Atlas (TCGA) database and 115 tumor samples from Gene Expression Omnibus (GEO). Meanwhile, we used the ImmPort database to determine the immune-related genes as well. Weighted gene correlation network analysis, Cox regression analysis and least absolute shrinkage and selection operator (LASSO) analysis were used to identify the key immune related genes (IRGs) which are closely related to prognosis. Gene set enrichment analysis (GSEA) was implemented to explore the difference of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway between Immune high- and low-risk score groups. Finally, we made a prognostic nomogram including Immune-Risk score and other clinicopathologic factors. A total of 318 genes from prognosis related modules were identified through weighted gene co-expression network analysis (WGCNA). 46 genes were strongly linked to prognosis after univariate Cox analysis. We constructed a seven genes prognostic signature which showed powerful prediction ability in both training cohort and testing cohort. 16 significant KEGG pathways were identified between high- and low- risk score groups using GSEA analysis. This study identified and verified seven immune-related prognostic biomarkers for the patients with HCC, which have potential value for immune modulatory and therapeutic targets.

Download Full-text

Construction of a novel immune gene-based model for prognosis prediction of colorectal cancer

10.21203/rs.3.rs-279544/v1 ◽

2021 ◽

Author(s):

Bin Xie ◽

jie lin

Keyword(s):

Gene Expression ◽

Cox Regression ◽

Expression Profiles ◽

Colon Adenocarcinoma ◽

Gene Set Enrichment Analysis ◽

Immune Gene ◽

Prognostic Signature ◽

Cox Regression Analysis ◽

Risk Of Death ◽

Immune Related Genes

Abstract Background Colon adenocarcinoma (COAD) is the third leading cause of cancer-related death. Although surgical treatment and chemotherapy of COAD have made significant progress, its immunotherapy also has great potential, nowadays. Methods Gene expression profiles and clinical data of COAD patients were obtained from The Cancer Genome Atlas_Colon Adenocarcinoma (TCGA_COAD) and Gene Expression Omnibus (GEO) databases, which were further detected for immune-related genes. Immune-related genes were downloaded from Immunology Database and Analysis Portal (ImmPort). LASSO Cox regression analysis was utilized to analyze the immune-related prognostic signature. The prognostic value of the signature was validated by ROC curve. To further detected the potential pathway about immune-related genes in COAD patients, Gene Set Enrichment Analysis (GESA) was used to identify the most significant pathways. Results Finally, a total of 436 immune-related mRNA were identified. Eleven prognosis-related genes were selected to establish an immune-related prognostic signature, which divided patients into high and low risk groups. Several biological processes, such as immune response was enriched. Moreover, our prognosis model has better performance in predicting the 1-, 3-, 5- and 8-years overall survival (OS) for patients from the TCGA and GEO cohort. Also, the complicated signature obtained by combining immune-related signatures with clinical factors provides a more accurate OS predicting compared with individual molecular signatures. Conclusion We have established a prognostic signature consisting of 11 immune-related genes, which may be potential biomarkers for identifying COAD with a high risk of death. Then, the possibility including immunotherapy in personalized COAD treatment was evaluated.

Download Full-text

Identification of a Five-Autophagy-Related-lncRNA Signature as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

Frontiers in Molecular Biosciences ◽

10.3389/fmolb.2020.611626 ◽

2021 ◽

Vol 7 ◽

Author(s):

Xiaoyu Deng ◽

Qinghua Bi ◽

Shihan Chen ◽

Xianhua Chen ◽

Shuhui Li ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

High Risk ◽

Cox Regression ◽

Risk Group ◽

High Risk Group ◽

Gene Set Enrichment Analysis ◽

The Cancer Genome Atlas ◽

Prognostic Signature ◽

Prediction Ability ◽

Cox Regression Analysis

Although great progresses have been made in the diagnosis and treatment of hepatocellular carcinoma (HCC), its prognostic marker remains controversial. In this current study, weighted correlation network analysis and Cox regression analysis showed significant prognostic value of five autophagy-related long non-coding RNAs (AR-lncRNAs) (including TMCC1-AS1, PLBD1-AS1, MKLN1-AS, LINC01063, and CYTOR) for HCC patients from data in The Cancer Genome Atlas. By using them, we constructed a five-AR-lncRNA prognostic signature, which accurately distinguished the high- and low-risk groups of HCC patients. All of the five AR lncRNAs were highly expressed in the high-risk group of HCC patients. This five-AR-lncRNA prognostic signature showed good area under the curve (AUC) value (AUC = 0.751) for the overall survival (OS) prediction in either all HCC patients or HCC patients stratified according to several clinical traits. A prognostic nomogram with this five-AR-lncRNA signature predicted the 3- and 5-year OS outcomes of HCC patients intuitively and accurately (concordance index = 0.745). By parallel comparison, this five-AR-lncRNA signature has better prognosis accuracy than the other three recently published signatures. Furthermore, we discovered the prediction ability of the signature on therapeutic outcomes of HCC patients, including chemotherapy and immunotherapeutic responses. Gene set enrichment analysis and gene mutation analysis revealed that dysregulated cell cycle pathway, purine metabolism, and TP53 mutation may play an important role in determining the OS outcomes of HCC patients in the high-risk group. Collectively, our study suggests a new five-AR-lncRNA prognostic signature for HCC patients.

Download Full-text

A 13-Gene Metabolic Prognostic Signature Is Associated With Clinical and Immune Features in Stomach Adenocarcinoma

Frontiers in Oncology ◽

10.3389/fonc.2021.612952 ◽

2021 ◽

Vol 11 ◽

Author(s):

Zaisheng Ye ◽

Miao Zheng ◽

Yi Zeng ◽

Shenghong Wei ◽

He Huang ◽

...

Keyword(s):

Risk Score ◽

Molecular Mechanisms ◽

Cancer Metabolism ◽

Cox Regression ◽

The Cancer Genome Atlas ◽

Differentially Expressed ◽

Prognostic Signature ◽

Cox Regression Analysis ◽

Stomach Adenocarcinoma ◽

Prognostic Prediction

Patients with advanced stomach adenocarcinoma (STAD) commonly show high mortality and poor prognosis. Increasing evidence has suggested that basic metabolic changes may promote the growth and aggressiveness of STAD; therefore, identification of metabolic prognostic signatures in STAD would be meaningful. An integrative analysis was performed with 407 samples from The Cancer Genome Atlas (TCGA) and 433 samples from Gene Expression Omnibus (GEO) to develop a metabolic prognostic signature associated with clinical and immune features in STAD using Cox regression analysis and least absolute shrinkage and selection operator (LASSO). The different proportions of immune cells and differentially expressed immune-related genes (DEIRGs) between high- and low-risk score groups based on the metabolic prognostic signature were evaluated to describe the association of cancer metabolism and immune response in STAD. A total of 883 metabolism-related genes in both TCGA and GEO databases were analyzed to obtain 184 differentially expressed metabolism-related genes (DEMRGs) between tumor and normal tissues. A 13-gene metabolic signature (GSTA2, POLD3, GLA, GGT5, DCK, CKMT2, ASAH1, OPLAH, ME1, ACYP1, NNMT, POLR1A, and RDH12) was constructed for prognostic prediction of STAD. Sixteen survival-related DEMRGs were significantly related to the overall survival of STAD and the immune landscape in the tumor microenvironment. Univariate and multiple Cox regression analyses and the nomogram proved that a metabolism-based prognostic risk score (MPRS) could be an independent risk factor. More importantly, the results were mutually verified using TCGA and GEO data. This study provided a metabolism-related gene signature for prognostic prediction of STAD and explored the association between metabolism and the immune microenvironment for future research, thereby furthering the understanding of the crosstalk between different molecular mechanisms in human STAD. Some prognosis-related metabolic pathways have been revealed, and the survival of STAD patients could be predicted by a risk model based on these pathways, which could serve as prognostic markers in clinical practice.

Download Full-text

Development of a prognostic signature based on six immune related lncRNAs for hepatocellular carcinoma.

10.21203/rs.3.rs-16348/v1 ◽

2020 ◽

Author(s):

Ze-bing Song ◽

Guo-pei Zhang ◽

shaoqiang li

Keyword(s):

Hepatocellular Carcinoma ◽

Regression Analysis ◽

Cox Regression ◽

Enrichment Analysis ◽

Gene Set Enrichment Analysis ◽

The Cancer Genome Atlas ◽

Differentially Expressed ◽

Prognostic Signature ◽

Cox Regression Analysis ◽

Cerna Network

Abstract Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world which prognosis is poor. Therefore, a precise biomarker is needed to guide treatment and improve prognosis. More and more studies have shown that lncRNAs and immune response are closely related to the prognosis of hepatocellular carcinoma. The aim of this study was to establish a prognostic signature based on immune related lncRNAs for HCC.Methods: Univariate cox regression analysis was performed to identify immune related lncRNAs, which had negative correlation with overall survival (OS) of 370 HCC patients from The Cancer Genome Atlas (TCGA). A prognostic signature based on OS related lncRNAs was identified by using multivariate cox regression analysis. Gene set enrichment analysis (GSEA) and a competing endogenous RNA (ceRNA) network were performed to clarify the potential mechanism of lncRNAs included in prognostic signature. Results: A prognostic signature based on OS related lncRNAs (AC145207.5, AL365203.2, AC009779.2, ZFPM2-AS1, PCAT6, LINC00942) showed moderately in prognosis prediction, and related with pathologic stage (Stage I&II VS Stage III&IV), distant metastasis status (M0 VS M1) and tumor stage (T1-2 VS T3-4). CeRNA network constructed 15 aixs among differentially expressed immune related genes, lncRNAs included in prognostic signature and differentially expressed miRNA. GSEA indicated that these lncRNAs were involved in cancer-related pathways. Conclusion: We constructed a prognostic signature based on immune related lncRNAs which can predict prognosis and guide therapies for HCC.

Download Full-text

A signature of seven immune‐related genes predicts overall survival in male gastric cancer patients

Cancer Cell International ◽

10.1186/s12935-021-01823-0 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Xin Xu ◽

Yida Lu ◽

Youliang Wu ◽

Mingliang Wang ◽

Xiaodong Wang ◽

...

Keyword(s):

Gene Expression ◽

Gastric Cancer ◽

Overall Survival ◽

Risk Score ◽

Cox Regression ◽

External Validation ◽

The Cancer Genome Atlas ◽

Differentially Expressed ◽

Survival Prediction ◽

Immune Related Genes

Abstract Background Gastric cancer (GC) has a high mortality rate and is one of the most fatal malignant tumours. Male sex has been proven as an independent risk factor for GC. This study aimed to identify immune-related genes (IRGs) associated with the prognosis of male GC. Methods RNA sequencing and clinical data were obtained from The Cancer Genome Atlas (TCGA) database. Differentially expressed IRGs between male GC and normal tissues were identified by integrated bioinformatics analysis. Univariate and multivariate Cox regression analyses were applied to screen survival-associated IRGs. Then, GC patients were separated into high- and low-risk groups based on the median risk score. Furthermore, a nomogram was constructed based on the TCGA dataset. The prognostic value of the risk signature model was evaluated by Kaplan-Meier curve, receiver operating characteristic (ROC), Harrell’s concordance index and calibration curves. In addition, the gene expression dataset from the Gene Expression Omnibus (GEO) was also downloaded for external validation. The relative proportions of 22 types of infiltrating immune cells in each male GC sample were evaluated using CIBERSORT. Results A total of 276 differentially expressed IRGs were screened, including 189 up-regulated and 87 down-regulated genes. Subsequently, a seven-IRGs signature (LCN12, CCL21, RNASE2, CGB5, NRG4, AGTR1 and NPR3) was identified to be significantly associated with the overall survival (OS) of male GC patients. Survival analysis indicated that patients in the high-risk group exhibited a poor clinical outcome. The results of multivariate analysis revealed that the risk score was an independent prognostic factor. The established nomogram could be used to evaluate the prognosis of individual male GC patients. Further analysis showed that the prognostic model had excellent predictive performance in both TCGA and validated cohorts. Besides, the results of tumour-infiltrating immune cell analysis indicated that the seven-IRGs signature could reflect the status of the tumour immune microenvironment. Conclusions Our study developed a novel seven-IRGs risk signature for individualized survival prediction of male GC patients.

Download Full-text

Construction and Validation of a Reliable Six-Gene Prognostic Signature Based on the TP53 Alteration for Hepatocellular Carcinoma

Frontiers in Oncology ◽

10.3389/fonc.2021.618976 ◽

2021 ◽

Vol 11 ◽

Author(s):

Junyu Huo ◽

Liqun Wu ◽

Yunjin Zang

Keyword(s):

Gene Expression ◽

Hepatocellular Carcinoma ◽

Regression Analysis ◽

Cox Regression ◽

Enrichment Analysis ◽

Gene Set Enrichment Analysis ◽

Prognostic Signature ◽

Gene Set Enrichment ◽

Cox Regression Analysis ◽

Gene Set

BackgroundThe high mutation rate of TP53 in hepatocellular carcinoma (HCC) makes it an attractive potential therapeutic target. However, the mechanism by which TP53 mutation affects the prognosis of HCC is not fully understood.Material and ApproachThis study downloaded a gene expression profile and clinical-related information from The Cancer Genome Atlas (TCGA) database and the international genome consortium (ICGC) database. We used Gene Set Enrichment Analysis (GSEA) to determine the difference in gene expression patterns between HCC samples with wild-type TP53 (n=258) and mutant TP53 (n=116) in the TCGA cohort. We screened prognosis-related genes by univariate Cox regression analysis and Kaplan–Meier (KM) survival analysis. We constructed a six-gene prognostic signature in the TCGA training group (n=184) by Lasso and multivariate Cox regression analysis. To assess the predictive capability and applicability of the signature in HCC, we conducted internal validation, external validation, integrated analysis and subgroup analysis.ResultsA prognostic signature consisting of six genes (EIF2S1, SEC61A1, CDC42EP2, SRM, GRM8, and TBCD) showed good performance in predicting the prognosis of HCC. The area under the curve (AUC) values of the ROC curve of 1-, 2-, and 3-year survival of the model were all greater than 0.7 in each independent cohort (internal testing cohort, n = 181; TCGA cohort, n = 365; ICGC cohort, n = 229; whole cohort, n = 594; subgroup, n = 9). Importantly, by gene set variation analysis (GSVA) and the single sample gene set enrichment analysis (ssGSEA) method, we found three possible causes that may lead to poor prognosis of HCC: high proliferative activity, low metabolic activity and immunosuppression.ConclusionOur study provides a reliable method for the prognostic risk assessment of HCC and has great potential for clinical transformation.

Download Full-text

Identification of an autophagy-related gene signature for survival prediction in patients with cervical cancer

Journal of Ovarian Research ◽

10.1186/s13048-020-00730-8 ◽

2020 ◽

Vol 13 (1) ◽

Author(s):

Hengyu Chen ◽

Qingchun Deng ◽

Wenwen Wang ◽

Huishan Tao ◽

Ying Gao

Keyword(s):

Cervical Cancer ◽

High Risk ◽

Risk Score ◽

Squamous Cell ◽

Cox Regression ◽

The Cancer Genome Atlas ◽

Differentially Expressed ◽

Survival Prediction ◽

Prognostic Signature ◽

Cox Regression Analysis

Abstract Cervical cancer is one of the most common female malignancy that occurs worldwide and is reported to cause over 300,000 deaths in 2018. Autophagy controls the survival and death of cancerous cells by regulating the degradation process of cytoplasm and cellular organelle. In the present study, the differentially expressed autophagy-related genes (ARGs) between healthy and cancerous cervical tissues (squamous cell neoplasms) were obtained using data from GTEx and The Cancer Genome Atlas (TCGA) database. The functionalities of the differentially expressed ARGs were analyzed using Gene Ontology (GO) as well as the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Next, we conducted univariate Cox regression assay and obtained 12 ARGs that were associated with the prognosis of cervical cancer patients. We carried out a multivariate Cox regression analysis and developed six ARG-related prognostic signature for the survival prediction of patients with squamous cell cervical cancer (Risk score = − 0.63*ATG3–0.42*BCL2 + 0.85*CD46–0.38*IFNG+ 0.23*NAMPT+ 0.82*TM9SF1). Following the calculation of risk score using the signature, the patients were divided into high and low-risk groups according to the median value. Kaplan-Meier curve demonstrated that patients with a high-risk score tend to have a poor prognosis (P < 0.001). The value for area under the curves corresponding to the receiver operating characteristic (ROC) was 0.740. As observed, the expression of IFNG was negatively associated with lymph node metastasis (P = 0.026), while a high-risk score was significantly associated with increased age (P = 0.008). To further validate the prognostic signature, we carried out a permutation test and confirmed the performance of the risk score. In conclusion, our study developed six ARG-related prognostic signature for patients with squamous cell cervical cancer, which might help in improving the prognostic predictions of such patients.

Download Full-text

Development of a prognostic signature for esophageal cancer based on nine immune related genes

10.21203/rs.3.rs-56334/v2 ◽

2020 ◽

Author(s):

zhi Zhang ◽

cheng chen ◽

ying fang ◽

sheng Li ◽

xiaohua Wang ◽

...

Keyword(s):

T Cells ◽

Esophageal Cancer ◽

Prognostic Model ◽

Cox Regression ◽

Risk Group ◽

The Cancer Genome Atlas ◽

Receptor Interaction ◽

Prognostic Signature ◽

Cox Regression Analysis ◽

Immune Related Genes

Abstract Background: Function of the immune system is correlated with the prognosis of the tumor. The effect of immune microenvironment on esophageal cancer (EC) development has not been fully investigated. Methods: This study aimed to explore a prognostic model based on immune-related genes (IRGs) for EC. We obtained the RNA-seq dataset and clinical information of EC from the Cancer Genome Atlas (TCGA). Results: We identified 247 upregulated IRGs and 56 downregulated IRGs. Pathway analysis revealed that the most differentially expressed IRGs were enriched in Cytokine-cytokine receptor interaction. We further screened 13 survival-related IRGs and constructed regulatory networks involving related transcription factors (TFs). Finally, a prognostic model was constructed with 9 IRGs (HSPA6, S100A12, CACYBP, NOS2, DKK1, OSM ,STC2 ,NGPTL3 and NR2F2) by multivariate Cox regression analysis. The patients were classified into two subgroups with different outcomes. When adjusted with clinical factors, this model was verified as an independent predictor, which performed accurately in prognostic prediction. Next, M0 and M2 macrophages and activated mast cells were significantly enriched in high-risk group, while CD8 T cells and regulatory T cells (Tregs) were significantly enriched in low-risk group. Conclusions: Prognosis related IRGs were identified and a prognostic signature for esophageal cancer based on nine IRGs was developed.

Download Full-text

Development and Validation of a Novel Glycolysis-Related Risk Signature for Predicting Survival in Pancreatic Adenocarcinoma

10.21203/rs.3.rs-29859/v1 ◽

2020 ◽

Author(s):

Ang Li ◽

Sinan Hou ◽

Jian Chen ◽

Huimin Hou ◽

Yanfang Jiang

Keyword(s):

Regression Analysis ◽

Pancreatic Adenocarcinoma ◽

Risk Score ◽

Cox Regression ◽

Risk Groups ◽

Gene Signature ◽

Gene Set Enrichment Analysis ◽

Survival Prediction ◽

Cox Regression Analysis ◽

Related Risk

Abstract Background Pancreatic adenocarcinoma (PAAD) is one of the leading causes of cancer death worldwide. Through data mining, an increasing number of biomarkers have been identified for predicting survival of PAAD. However, the ability of single gene biomarkers to predict patient survival is still insufficient. This study aimed to develop a novel risk signature for predicting survival of PAAD. Methods mRNA expression profiling was performed in a large PAAD cohort (N = 177) from The Cancer Genome Atlas (TCGA) database. Gene Set Enrichment Analysis (GSEA) was analyzed to detect whether the gene sets showed statistically differences between PAAD and adjacent normal tissues. Univariate Cox regression analysis was used to analyze and identify genes related to overall survival (OS), then subjected to multivariable Cox regression to further confirm the prognostic genes and obtain the coefficients. The expression level of selected genes weighted by their coefficients through linearly combining, we constructed a risk score formula for prognostic prediction. The three-mRNA signature for survival prediction is validated by Kaplan–Meier curve analysis. Results We demonstrated that a set of three genes (KIF20A, CHST2, and MET) were significantly associated with OS. Based on this three-gene signature, 177 PAAD patients were classified into high-risk groups and low-risk groups using the median risk score as cut off value. Additionally, multivariate Cox regression analysis revealed that the three-gene signature had independent prognostic value. Conclusions To our best knowledge, we first develop a glycolysis-related risk signature for predicting survival of pancreatic adenocarcinoma. The findings provide insight into identification of patients with poor prognosis in PAAD and improve novel therapy targets for this disease.

Download Full-text